



Aalen/Germany, 5 May 2026

ZEISS to present new clinical study results on novel myopia management lens ZEISS MyoActive at ARVO 2026

New interim study data from ZEISS's myopia control portfolio shows ZEISS MyoActive demonstrating high efficacy in slowing myopia progression. In addition, ZEISS presents first clinical insights on ZEISS MyoEase lenses, as well as the latest clinical results from the established ZEISS MyoCare portfolio.

- Interim results for the novel ZEISS MyoActive spectacle lens demonstrate robust efficacy, significantly slowing myopia progression over 6 months.
- One-year cross-over data for ZEISS MyoEase showed a high responder rate, delivering significant reductions in refractive error progression and axial elongation – with no evidence of rebound after switching back to single vision lenses.
- Three-year multi-center results for the ZEISS MyoCare portfolio confirm sustained long-term benefits in slowing myopia progression.

ZEISS MyoActive: A novel lens design for myopia management

ZEISS MyoActive lenses use innovative defocus patterns to reduce neural adaptation and maximise treatment efficacy. After 6 months of lens wear, children wearing ZEISS MyoActive lenses showed minimal change: 0.13D and 0.02mm progression on average. This represents a substantial reduction in both refractive error and axial length growth of 0.38D and 0.15mm on average compared to single vision (SV) lenses, highlighting ZEISS MyoActive's high efficacy.¹

"ZEISS MyoActive represents a major step forward in spectacle-based myopia management," says Prof Padmaja Sankaridurg, who presented the study results for ZEISS. "The evidence is so strong that it makes ZEISS MyoActive the perhaps most important addition to ZEISS's myopia management portfolio."

ZEISS MyoEase lenses are an effective tool for myopia management

Clinical results from a one-year cross-over trial in Asia show that ZEISS MyoEase spectacle lenses significantly slow myopia progression as compared to SV lenses, with no indication for a rebound

¹ Sankaridurg, P., et al. (2026, May 3-7). 6-month myopia control efficacy of five novel spatially variant, defocus spectacles. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Denver, CO, United States.



effect as children switched back to SV lenses.² Averaged across the two stages of the cross-over trial, the difference of progression between ZEISS MyoEase and SV lenses for spherical equivalent refractive error (SE) and axial length (AL) were 0.28D average reduction of refractive error and 0.12mm average reduction of AL progression over 6 months.² Eight out of 10 children showed slower myopia progression with ZEISS MyoEase lenses.³ This increased to nearly 9 out of 10 children when lenses were worn for ≥ 12 hours daily.

ZEISS MyoCare continues to slow myopia progression, as shown in three-year clinical results

In two ongoing multi-center clinical trials across China and Europe, ZEISS MyoCare lenses are being assessed to ensure a comprehensive, long-term and robust evaluation of their effectiveness in slowing myopia. In Asian children, after three years of wear, as compared to single vision (SV) lenses, ZEISS MyoCare slowed myopia progression on average by 0.62D and 0.28mm and ZEISS MyoCare S by 0.45D and 0.18mm.⁴ In Caucasian children, after two years of wear, ZEISS MyoCare slowed myopia progression on average by 0.37D and 0.22mm.⁵ The lenses reduced both the risk and severity of rapid myopia progression (-0.50 D or greater spherical equivalent refractive error and $+0.20$ mm or greater axial length elongation over two years) by 76%⁶ compared to SV.

ZEISS Myopia Management Collective

Building on this growing body of clinical evidence, ZEISS is translating scientific insights into a comprehensive ecosystem for effective myopia management to support eye care professionals throughout the entire myopia journey. This ecosystem, the ZEISS Myopia Management Collective, enables proactive, effective, and sustainable myopia management for younger patients. It delivers a portfolio of evidence-based products, solutions, and services, all grounded in robust scientific research and continuous innovation.

The posters presented at the 2026 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) can be found here: <https://zeiss.com/vision-myopia>

² Du, L., et al. (2026, May 3-7). Slowing myopia progression with a novel spectacle lens – 1 year, randomized double-blind, cross over clinical trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Denver, CO, United States.

³ Liu, N., et al. (2026, May 3-7). Responders and non-responders to wear of a novel myopia control spectacle lens: A 12-month randomized, double-masked, cross-over clinical trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Denver, CO, United States.

⁴ Chen, X., et al. (2026, May 3-7). Slowing myopia progression with cylindrical annular refractive elements (CARE) – results from a 3-year prospective multi-center trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Denver, CO, United States.

⁵ Alvarez-Peregrina, C., et al. (2026, May 3-7). Two-year evolution of Cylindrical Annular Refractive Elements (CARE) lens efficacy. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Denver, CO, United States.

⁶ Sanchez Tena, M.A., et al. (2026, May 3-7). Risk factors and protective effect of CARE spectacle lenses on rapid myopia progression in European children. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Denver, CO, United States.

Press Release

ZEISS Vision Care



ZEISS, MyoActive, MyoEase, MyoCare and C.A.R.E. are trademarks of Carl Zeiss AG and/or other companies of the Carl Zeiss Group.

Not all products, services or offers are approved or offered in every market and approved labelling and instructions may vary from one country to another.

Press contact

ZEISS Vision Care
Sarah Kopp
Phone: +49 160 95 69 28 58
Email: sarah.kopp@zeiss.com

www.zeiss.com/newsroom
www.zeiss.com/vision-newsroom

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totalling almost 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets (September 30, 2025).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses, and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare, and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 46,600 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 30 production facilities worldwide (September 30, 2025). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Vision Care

ZEISS Vision Care, part of ZEISS Consumer Markets segment, develops and manufactures comprehensive solutions for the entire value chain of ophthalmic optics. The portfolio includes top-quality eyeglass lenses, partner programs, ophthalmic instruments, services, digital solutions and apps for both eye care professionals and consumers, as well as care products for the eye and beyond. As one of the world's leading manufacturers of eyeglass lenses and the best-known prescription eyeglass lens brand amongst consumers worldwide, ZEISS is focused on optimal visual comfort and individualized vision solutions. With a passion for innovation and quality, ZEISS Vision Care is committed to protecting and enhancing people's vision and contributing to lifelong visual health.